The US president says the levies on pharmaceutical imports are imminent, but won’t take effect for a year to a year and a ...

Edward Ahn, CEO of MEDIPOST, Inc., reacts to the challenge of launching orphan drugs without complete evidence, particularly ...

The Craigavon investment enhances Almac’s global clinical supply network with upgraded storage, distribution, and shipping ...

In the second part of his Pharma Commerce video interview, Marschall Runge, MD, PhD, dean of the University of Michigan Medical School and author of The Great Healthcare Disruption, outlines how the ...

In the United States, Medicaid is considered the largest payer of healthcare, serving nearly a quarter of the total population; this includes nearly 40 million children. And in a separate analysis, ...

In a video interview with Pharma Commerce, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, discusses the evolving state of global cell and gene therapy commercialization. Sawicki highlighted ...

Classic and recent examples Classic examples illustrate the application of these strategies. For instance, Cialis (tadalafil) is marketed for erectile dysfunction, while Adcirca (also tadalafil) is ...

How CRO Partnerships Are Evolving to Meet Changing Industry Demands In an interview with Applied Clinical Trials, Judith Ng-Cashin, MD, chief medical officer, Novotech, emphasized the need for CRO ...

In the fourth part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, explains the lessons pharma leaders in traditional therapeutic areas can learn from ...

PC: What role has public participation historically played in shaping healthcare policy, and why is it important for pharma and biotech companies? Leuchter: Public participation has played a critical ...

Oncology Care Index Spurs J&J to Address Fragmentation in Cancer Treatment In an interview with Pharmaceutical Executive, Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson ...

Key Takeaways Price hikes, not launch prices, drove the GTN bubble. The real driver of the gross-to-net (GTN) bubble was the pharmaceutical industry's ability to raise drug prices year after ...